Biostate AI Secures $4M in Funding to Advance Generative AI for Human Health
Biostate AI is pioneering the use of AI and biotechnology to create advanced tools for the analysis of biological data.
Company Name: Biostate AI
Location: Palo Alto, CA, USA
Sector: Biotechnology, Artificial Intelligence
Funding Details: Raised $4M in funding. The round was led by Matter Venture Partners, with participation from Vision Plus Capital, Catapult VC, the Caltech Seed Fund, and notable individuals such as Dario Amodei (CEO of Anthropic), Joris Poort (CEO of Rescale), Michael Schnall-Levin (CTO of 10X Genomics), and Emily Leproust (CEO of Twist Bioscience).
Purpose of Investment: To expand operations and development efforts.
Leadership: Led by CEO David Zhang. Founded in 2023, Biostate AI is committed to enhancing human health through innovative generative AI technologies.
Product: Biostate AI specializes in scalable biodata analysis using its proprietary Barcode-Integrated Reverse Transcription (BIRT) technology for Total RNA sequencing. This allows for comprehensive analysis of various RNA types, enhancing research capabilities in genetics. Additionally, the company has launched OmicsWeb Copilot, a conversational AI tool designed to assist biologists in analyzing and visualizing data. This platform uses large language models to create customized software and scripts for data analysis and provides access to a significant collection of RNAseq datasets.
About Company: Biostate AI is pioneering the use of AI and biotechnology to create advanced tools for the analysis of biological data. With facilities in Palo Alto, CA, and Houston, TX, the company collaborates extensively with academic, nonprofit, and industry partners to develop technology and collect multiomic biodata. This funding will enable Biostate AI to further its mission of making biological data collection more efficient and cost-effective, thereby accelerating scientific discovery and applications in health.
